<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25787" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neurofibromatosis Type 2</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tiwari</surname>
            <given-names>Ruchi</given-names>
          </name>
          <aff>Un of Texas Health Sci Ctr San Antonio</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Achint K.</given-names>
          </name>
          <aff>Un of Texas Health Sci Ctr San Antonio</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ruchi Tiwari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Achint Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25787.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple tumors involving the central nervous system (CNS). Bilateral vestibular schwannomas are the hallmark feature of NF2 and are present in approximately 90 to 95 percent of patients. Meningiomas are seen in approximately 50 percent of patients with NF2. This activity reviews the presentation, evaluation, and management of NF2 and highlights the role of the interprofessional team in the care of these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of neurofibromatosis type 2.</p></list-item><list-item><p>Evaluate&#x000a0;the typical presentation of a patient with neurofibromatosis type 2.</p></list-item><list-item><p>Assess&#x000a0;the treatment and management options available for neurofibromatosis type 2.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination and communication to advance the treatment of neurofibromatosis type 2 and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25787&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25787">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25787.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple&#x000a0;tumors involving the central nervous system (CNS).<xref ref-type="bibr" rid="article-25787.r1">[1]</xref>&#x000a0;See <bold>Image.</bold>&#x000a0;Neurofibromatosis.</p>
      </sec>
      <sec id="article-25787.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>NF2 is inherited as an autosomal dominant trait in some patients. The abnormal gene can be inherited from either of the parents, and the risk of passing the gene to offspring from a parent is 50%. There is no family history in some patients with NF2; the disease is caused by a de novo mutation in the <italic toggle="yes">NF2</italic> gene. NF2 is caused by mutations in the <italic toggle="yes">NF2</italic> gene located in the long arm of chromosome number 22 (22q12.2). The <italic toggle="yes">NF2</italic> gene encodes for the protein known as merlin, which acts as a tumor suppressor gene.<xref ref-type="bibr" rid="article-25787.r2">[2]</xref>&#x000a0;Merlin is found in the Schwann cells in the nervous system.<xref ref-type="bibr" rid="article-25787.r3">[3]</xref></p>
      </sec>
      <sec id="article-25787.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of NF2 is about 1 in 25,000 to 40,000 individuals.</p>
      </sec>
      <sec id="article-25787.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Bilateral vestibular schwannomas are the hallmark feature of NF2 and are present in approximately 90% to 95% of patients.&#x000a0;Meningiomas are&#x000a0;seen in approximately 50% of patients with NF2.</p>
      </sec>
      <sec id="article-25787.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Vestibular schwannomas are benign tumors involving the vestibular portion of the vestibulocochlear nerve (CN VIII). The most common location is an inferior vestibular nerve. They are well-circumscribed encapsulated tumors arising from the perineural elements of the Schwann cells. They usually cause splaying and displacement of the nerve fibers rather than engagement. Microscopically,&#x000a0;2 types of&#x000a0;cellular architecture can be seen in these tumors: Antoni A and B.<xref ref-type="bibr" rid="article-25787.r4">[4]</xref>&#x000a0;Antoni A-type&#x000a0;regions have dense cellularity with closely packed elongated nuclei alternated with clear zones devoid of nuclei (Verocay bodies). Antoni B-type regions are less cellular and contain more loosely arranged cells. The volume of Antoni B regions in any given tumor is variable and may be absent.</p>
      </sec>
      <sec id="article-25787.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>NF2 patients typically present with tumor-related symptoms around 20 years of age. The most common intracranial tumor associated with NF2 is vestibular schwannoma, which is typically bilateral in these patients. Patients typically present with tinnitus, sensorineural hearing loss, and balance problems. The cutaneous features in NF2 are less common and more subtle than NF1. The most common skin&#x000a0;finding is an elevated plaque-like lesion, which may be hyperpigmented compared to the surrounding skin. The other cutaneous abnormalities are subcutaneous nodules representing swelling of the nerves and cutaneous tumors, which generally represent schwannomas rather than neurofibromas. Patients with meningiomas develop symptoms based on location, including a headache, seizures, or focal neurological symptoms. NF2 patients tend to develop meningiomas earlier than those with sporadic meningiomas. Approximately 20% of children with meningiomas have NF2. Patients with intraspinal tumors present with pain, muscular weakness, and paresthesia.</p>
        <p>The clinical diagnosis of NF2 is based on the presence of any 1 of the following criteria:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bilateral vestibular schwannomas less than 70 years of age</p>
          </list-item>
          <list-item>
            <p>Unilateral vestibular schwannoma before age 70 years and a first-degree relative with NF2</p>
          </list-item>
          <list-item>
            <p>Any&#x000a0;2 of the following: meningioma, schwannoma (non-vestibular), neurofibroma, glioma, cerebral calcification, cataract <italic toggle="yes">AND</italic> first-degree relative to NF2 <italic toggle="yes">OR</italic> unilateral vestibular schwannoma and negative LZTR1 testing</p>
          </list-item>
          <list-item>
            <p>Multiple meningiomas and unilateral vestibular schwannoma or any&#x000a0;2 of the following: schwannoma (non-vestibular), neurofibroma, glioma, cerebral calcification, cataract</p>
          </list-item>
          <list-item>
            <p>Constitutional or mosaic pathogenic <italic toggle="yes">NF2</italic> gene mutation from the blood or by the identification of an identical mutation from 2&#x000a0;separate tumors in the same individual.<xref ref-type="bibr" rid="article-25787.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25787.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Detailed clinical and family histories are required from the patients suspected of having NF2. A complete physical examination should be done to look for cutaneous schwannomas or plaque-like lesions, and an ophthalmic examination should be done to look for cataracts and optic nerve, among other things. Contrast-enhanced MRI of the brain and entire spine is recommended to evaluate schwannomas and meningiomas.</p>
        <p>Vestibular schwannoma has characteristic features in magnetic resonance imaging (MRI). It is located in the internal auditory canal, which is often widened. Large tumors also extend into the cerebellopontine angle and cause the typical "ice cream cone" appearance. These lesions are hypointense on T1-weighted images and hyperintense on T2-weighted images with intense contrast enhancement. Cystic changes can be seen in large tumors. There is a&#x000a0;poor correlation between the tumor size and the degree of hearing loss.</p>
        <p>Meningiomas are the most common extra-axial tumors in the brain. NF2 patients develop meningiomas at an earlier age, and they are often multiple. If meningiomas are seen in the pediatric age group, then a diagnosis of&#x000a0; NF2 should be considered. Meningiomas have typical features on the MRI. They are dural-based lesions with the isointense signal on T1-weighted images and iso to the hyperintense signal on T2-weighted images with intense enhancement and an enhancing dural tail.<xref ref-type="bibr" rid="article-25787.r6">[6]</xref></p>
        <p>Multiple spinal tumors&#x000a0;can also be seen in patients with NF2, including schwannomas, meningiomas, and ependymomas, and can be diagnosed with MRI. Schwannomas are the most common type; they typically arise from the dorsal root with the typical appearance of a dumbbell shape with the widening of the neural foramen and intense enhancement. Meningiomas enhance extramedullary lesions, typically seen in the cervical or thoracic region. Ependymomas are intramedullary lesions causing enlargement of the spinal cord with hemorrhage, cystic changes, and variable enhancement.<xref ref-type="bibr" rid="article-25787.r7">[7]</xref></p>
      </sec>
      <sec id="article-25787.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Multidisciplinary management is required in patients with NF2, including oncologists, neurologists, neuroradiologists, ophthalmologists, geneticists, and neurosurgeons. For tumor surveillance, an annual brain MRI is recommended. If no brain tumor is seen on the initial imaging, then MRI can be done every 2 years. If the tumor is seen, an MRI should be done twice in the first year, followed by an annual follow-up.</p>
        <p>Small asymptomatic vestibular schwannomas can be managed conservatively with MRI follow-up. Surgery is the primary treatment for large symptomatic vestibular schwannomas. Meningiomas are also treated surgically, with radiation treatment reserved for non-surgical candidates.[8] Spinal cord ependymomas are usually low-grade tumors and can be followed clinically,&#x000a0;with surgery reserved for symptomatic patients.</p>
        <p>Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is a new systemic immunotherapy for many tumors. Some studies have shown tumor regression and hearing improvement in NF2 patients treated with bevacizumab.<xref ref-type="bibr" rid="article-25787.r8">[8]</xref></p>
      </sec>
      <sec id="article-25787.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>NF2 should be differentiated from Schwannomatosis, another neurofibromatosis genetically distinct from NF1 and NF2&#x000a0;(see <bold>Image.</bold> Neurofibromatosis, NF1, NF2, and Schwannomatosis).&#x000a0;Schwannomatosis is most frequently sporadic, with 20% of cases being familial. Schwannomatosis is characterized by developing multiple schwannomas in the peripheral nervous system without concomitant involvement of the vestibular nerves. Nonvestibular cranial nerve schwannomas are uncommon but can be seen in these patients.<xref ref-type="bibr" rid="article-25787.r9">[9]</xref></p>
      </sec>
      <sec id="article-25787.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The outlook for these patients is guarded. If the tumors are detected late, the outcomes are poor, and the quality of life is reduced.</p>
      </sec>
      <sec id="article-25787.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications can occur depending on the location of the tumor and the proximity to vital parts of the brain. A few of them include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Weakness</p>
          </list-item>
          <list-item>
            <p>Hydrocephalus</p>
          </list-item>
          <list-item>
            <p>Cranial nerve deficits</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25787.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Proper education should be given to the patient about the disease, the likely complications, and the difficulty of offering a complete cure. Genetic counseling before conception would benefit.</p>
      </sec>
      <sec id="article-25787.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional management is required in patients with NF2, including oncologists, neurologists, neuroradiologists, ophthalmologists, geneticists, nurse practitioners, and neurosurgeons. For tumor surveillance, an annual brain MRI is recommended. If no brain tumor is seen on the initial imaging, then MRI can be done every&#x000a0;2 years. If the tumor is seen, then MRI should be done twice in the first year with&#x000a0;an annual follow-up after that.</p>
      </sec>
      <sec id="article-25787.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25787&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25787">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/neurofibromatosis-type-2/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25787">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25787/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25787">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25787.s16">
        <fig id="article-25787.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Neurofibromatosis, NF1, NF2, and Schwannomatosis. Neurofibromatosis encompasses three distinct disorders: neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis.&#x000a0; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="neurofibromatosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25787.s17">
        <fig id="article-25787.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Neurofibromatosis Contributed by S Verma, MBBS, DVD, FRCP, FAAD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Neurofibromatosis__SV1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25787.s18">
        <title>References</title>
        <ref id="article-25787.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinh</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Nisenbaum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chyou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Misztal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tekin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Telischi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fernandez-Valle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XZ</given-names>
              </name>
            </person-group>
            <article-title>Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.</article-title>
            <source>Otol Neurotol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>e529</fpage>
            <page-range>e529-e537</page-range>
            <pub-id pub-id-type="pmid">32150022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25787.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;rsoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Er&#x000e7;al</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Genetic Evaluation of Common Neurocutaneous Syndromes.</article-title>
            <source>Pediatr Neurol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>89</volume>
            <fpage>3</fpage>
            <page-range>3-10</page-range>
            <pub-id pub-id-type="pmid">30424961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25787.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shevde</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Merlin regulates signaling events at the nexus of development and cancer.</article-title>
            <source>Cell Commun Signal</source>
            <year>2020</year>
            <month>Apr</month>
            <day>16</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <pub-id pub-id-type="pmid">32299434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25787.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wippold</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Lubner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>L&#x000e4;mmle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neuropathology for the neuroradiologist: Antoni A and Antoni B tissue patterns.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>1633</fpage>
            <page-range>1633-8</page-range>
            <pub-id pub-id-type="pmid">17893219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25787.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Bulman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gokhale</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Rutherford</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hammerbeck-Ward</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.</article-title>
            <source>Neurology</source>
            <year>2017</year>
            <month>Jan</month>
            <day>03</day>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-92</page-range>
            <pub-id pub-id-type="pmid">27856782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25787.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of newly developed NF2 intracranial meningiomas through comparative analysis of pediatric and adult patients.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>194</volume>
            <fpage>105799</fpage>
            <pub-id pub-id-type="pmid">32229353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25787.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalamarides</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Essayed</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lejeune</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Aboukais</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sterkers</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bernardeschi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peyre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hammerbeck-Ward</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kellett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rutherford</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Pathmanaban</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Spinal ependymomas in NF2: a surgical disease?</article-title>
            <source>J Neurooncol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>136</volume>
            <issue>3</issue>
            <fpage>605</fpage>
            <page-range>605-611</page-range>
            <pub-id pub-id-type="pmid">29188529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25787.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mautner</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kutta</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fuensterer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bokemeyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hagel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Friedrich</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Panse</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.</article-title>
            <source>Neuro Oncol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-8</page-range>
            <pub-id pub-id-type="pmid">20150363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25787.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferner</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elgersma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DGR</given-names>
              </name>
              <name>
                <surname>Giovannini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Legius</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Messiaen</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Plotkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Schindeler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ullrich</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Widemann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.</article-title>
            <source>Am J Med Genet A</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>179</volume>
            <issue>6</issue>
            <fpage>1098</fpage>
            <page-range>1098-1106</page-range>
            <pub-id pub-id-type="pmid">30908866</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
